Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALML3 | P27482 | 6/20 | 0.51 |
| ▸ | MAOA | P21397 | 3/20 | 0.49 |
| ▸ | MAOB | P27338 | 3/20 | 0.49 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14603044 | 0.88 | F10 (0.53) | CALML3MAOAGRM2 | |
| SCHEMBL6271162 | 0.81 | GRM2 (0.38) | GRM2P2RX3 | |
| SCHEMBL5637293 | 0.81 | GRM2 (0.42) | GRM2 | |
| SCHEMBL9550251 | 0.79 | MAOA (0.59) | CALML3MAOAMAOBGRM2 | |
| SCHEMBL5637317 | 0.78 | MAOA (0.57) | MAOAGRM2 | |
| SCHEMBL9549439 | 0.77 | GRM2 (0.64) | CALML3MAOAMAOBGRM2 | |
| SCHEMBL9482302 | 0.77 | GRM2 (0.64) | CALML3MAOAMAOBGRM2 | |
| SCHEMBL6606264 | 0.76 | ITGB3 (0.58) | CALML3MAOAMAOBGRM2 | |
| SCHEMBL3323919 | 0.76 | MAOA (0.58) | CALML3MAOAMAOBGRM2 | |
| SCHEMBL7297166 | 0.76 | GRM2 (0.63) | CALML3MAOAMAOBGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157482-B2 | Antibacterial 1,3-oxazolidin-2-one derivatives | ASTRAZENECA AB (SE) | 2007-01-02 | — | — | US | disclosed |
| US-20060084810-A1 | Antibacterial 1,3-oxazolidin-2-one derivatives | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084810-A1 | Antibacterial 1,3-oxazolidin-2-one derivatives | HRH1, HDHD5, NGLY1 | CALML3 4277/4885MAOA 717/4885MAOB 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.